Psychopharmacology : A mental health professional's guide to commonly used medications.

Cover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia -- 2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia -- Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy -- Clozapine alert -- Other adverse effects of clozapine.

Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK�3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations -- Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion) -- Adverse effects and management -- Monoamine oxidase inhibitors -- Precautions, side effects and management -- Reversible inhibitor of monoamine oxidase type A (RIMA) -- Side effects -- Serotonin syndrome -- 3.5 Differences in therapeutic effects of antidepressants -- 4 Drugs used in dementia -- 4.1 Introduction -- Dementia assessment and diagnosis: best practice -- 4.2 Mechanism of action -- Acetylcholinesterase inhibitors -- 4.3 Dose and administration -- 4.4 Adverse effects and management -- Acetylcholinesterase inhibitors -- Cholinergic crisis -- Polypharmacy in the older person -- Antipsychotic therapy in the care of the older person -- 4.5 Memantine (NMDA receptor antagonist) -- Mechanism of action.

Concomitant use of cholinesterase inhibitors and memantine -- Adverse effects and management of memantine -- 5 Drugs used in bipolar disorder -- 5.1 Introduction -- The aetiology of bipolar disorder -- Bipolar disorder clinical presentation and management -- 5.2 Mechanism of action -- 5.3 Dose and administration -- Lithium -- Valproate -- Dose and administration of valproate -- Carbamazepine -- Dose and administration of carbamazepine -- Lamotrigine -- Dose and administration of lamotrigine -- 5.4 Adverse effects, monitoring and management -- Lithium -- Adverse effects -- Lithium toxicity -- Valproate -- Carbamazepine -- Lamotrigine -- 6 Drugs used in anxiety disorders -- 6.1 Introduction -- Types of anxiety -- Generalised anxiety disorder -- Panic disorder -- Social anxiety disorder -- Agoraphobia -- Separation anxiety -- Specific phobias -- Medication-induced anxiety disorder -- 6.2 Mechanism of action -- Benzodiazepine hypnotics and anxiolytics -- Non-benzodiazepine hypnotics -- Melatonin -- Non-benzodiazepine anxiolytics -- 6.3 Dose and administration -- 6.4 Adverse effects and management -- Adverse effects of benzodiazepines -- Paradoxical reaction -- Withdrawal from benzodiazepines -- Managing withdrawal symptoms -- Risk of overdose with benzodiazepines -- Treatment in overdose -- Adverse effects of non-benzodiazepine hypnotics (Z-drugs) -- Promethazine -- Precautions and interactions (benzodiazepines and hypnotics) -- Adverse effects of non-benzodiazepine anxiolytics -- Buspirone -- Pregabalin -- Beta blockers (propranolol) -- 7 Drugs used in alcohol and substance misuse -- 7.1 Introduction -- 7.2 Most vulnerable groups to substance use disorders -- 7.3 The mesolimbic dopamine circuit as the key reward pathway component -- How does cocaine and methamphetamine use affect the functioning of the reward circuit?.

7.4 Drug tolerance, dependence, addiction -- Tolerance -- Some facts about tolerance -- Dependence -- Addiction -- 7.5 The psychopharmacology of commonly used drug substances and their effects -- Club (party) drugs -- 7.6 Care planning and management of substance misuse disorders -- 7.7 Medications used to treat alcohol dependence, smoking cessation and other drug dependencies -- Drug-related deaths -- Severe mental illness and smoking cessation -- Appendix: Answers to chapter review questions and MCQs -- Chapter 1 -- Chapter 2 -- Chapter 3 -- Chapter 4 -- Chapter 5 -- Chapter 6 -- Chapter 7 -- ANSWERS TO MULTIPLE CHOICE QUESTIONS -- Study activity 1: Multiple choice questions -- Study activity 2: Multiple choice questions -- Study activity 3: Multiple choice questions -- Study activity 4: Multiple choice questions -- Study activity 5: Multiple choice questions -- Study activity 6: Multiple choice questions -- Study activity 7: Multiple choice questions -- Study activity 8: Multiple choice questions -- Study activity 9: Multiple choice questions -- Study activity 10: Multiple choice questions -- Study activity 11: Multiple choice questions -- Glossary -- References -- Index.

An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2022. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.